Trillium Therapeutics (TRIL) Downgraded by Zacks Investment Research to Hold

Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday. They currently have a $9.00 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price would indicate a potential upside of 13.21% from the stock’s previous close.

According to Zacks, “Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (do not eat) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (eat) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. “

TRIL has been the topic of several other research reports. ValuEngine raised shares of Trillium Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 1st. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Trillium Therapeutics in a research note on Thursday, December 14th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. Trillium Therapeutics has an average rating of “Hold” and a consensus target price of $12.33.

Shares of Trillium Therapeutics (NASDAQ TRIL) traded down $0.25 on Friday, reaching $7.95. 99,100 shares of the company’s stock traded hands, compared to its average volume of 110,533. Trillium Therapeutics has a 52 week low of $4.15 and a 52 week high of $13.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.33 and a current ratio of 6.33. The firm has a market cap of $91.71, a PE ratio of -2.10 and a beta of 1.78.

Institutional investors and hedge funds have recently made changes to their positions in the business. AWM Investment Company Inc. acquired a new position in shares of Trillium Therapeutics during the 2nd quarter valued at about $4,415,000. Janus Henderson Group PLC acquired a new position in shares of Trillium Therapeutics during the 2nd quarter valued at about $2,395,000. Tekla Capital Management LLC acquired a new position in shares of Trillium Therapeutics during the 2nd quarter valued at about $1,980,000. Sectoral Asset Management Inc boosted its position in shares of Trillium Therapeutics by 27.8% during the 3rd quarter. Sectoral Asset Management Inc now owns 234,248 shares of the biotechnology company’s stock valued at $1,206,000 after acquiring an additional 50,976 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its position in shares of Trillium Therapeutics by 88.9% during the 2nd quarter. Victory Capital Management Inc. now owns 146,571 shares of the biotechnology company’s stock valued at $645,000 after acquiring an additional 68,970 shares during the last quarter. 47.18% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally posted by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/3127364/trillium-therapeutics-tril-downgraded-by-zacks-investment-research-to-hold.html.

About Trillium Therapeutics

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company?s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.